{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibtosxxizmrossbsqcooazpxkqwmpobgczr6hkgrjx6xmsf7xbcwi",
    "uri": "at://did:plc:eovmz6dbqbanxpynuzivgyc4/app.bsky.feed.post/3mjmimv23eqg2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifzce55kwcevwp6it355boxvwxm3r54ud3jmgemrw2tgmmyynfc3y"
    },
    "mimeType": "image/jpeg",
    "size": 42272
  },
  "path": "/news/health/fda-eli-lily-safety-glp-1-weight-loss-pill-b2958345.html",
  "publishedAt": "2026-04-16T13:11:18.000Z",
  "site": "https://www.the-independent.com",
  "tags": [
    "Health",
    "News"
  ],
  "textContent": "At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be linked to liver, heart and gastrointestinal problems",
  "title": "FDA asks drugmaker Eli Lilly for more safety information on its new GLP-1 weight loss pill",
  "updatedAt": "2026-04-16T13:11:18.000Z"
}